Skip to content
Adam Torkildson – Lifestyle
Author:
Immix Biopharma, Inc.
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
May 21, 2026
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
May 21, 2026
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
April 9, 2026
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
March 30, 2026